痰热清注射液对产ESBLs大肠埃希菌耐药性影响的研究
|
摘要
大肠埃希菌是最常见的社区及医院内获得性感染的病原菌之一。其中,产超广谱β-内酰胺酶(ESBLs)大肠埃希菌引起的感染又在大肠埃希菌引起的感染中占据首位,该细菌能够水解青霉素类抗生素,以及第一、第二、第三代和部分第四代头孢菌素,并且部分产ESBLs大肠埃希菌同时对氨基糖苷类和氟喹诺酮类抗生素也耐药。于是这些产ESBLs大肠埃希菌株引起的感染,可供选择的抗生素较少,并且治疗效果往往不理想,导致患者病死率上升,给临床治疗带来了较大的困难,同时也使医疗费用增加,带来了较重的社会经济负担。
许多研究报道某些中药方剂在体内具有良好的抗菌作用,尤其是在治疗或联合抗生素治疗耐药菌感染的疾病上,取得了较好的临床疗效。而且某些中药在体外对临床常见耐药菌具有较强的抗菌作用,因此深入研究中药对耐药菌耐药性的影响,有望为解决目前严峻的细菌耐药问题提供新的途径。
本论文主要包括文献综述、北京中医药大学东方医院2010年主要细菌耐药性监测、实验研究3部分。
1文献综述
分为3部分,分别介绍了中药抗菌作用的研究进展、痰热清抗感染作用的研究进展以及产ESBLs大肠埃希菌的研究进展。
2北京中医药大学东方医院2010年主要病原菌耐药性监测
目的：了解2010年北京中医药大学东方医院主要细菌的检出率及对抗生素的耐药状况。
方法：参照《全国临床检验操作规程》第2版获取细菌标本。参照CLSI推荐的方法,采用全自动微生物鉴定和药敏分析系统VITEK-32进行细菌鉴定以及药敏实验。
结果：2010年1月至12月东方医院共分离细菌3489株,占前5位的细菌及其比例分别是：大肠埃希菌(17.71%)、铜绿假单胞菌(17.25%)、金黄色葡萄球菌(12.81%)、鲍曼复合醋酸钙不动杆菌(10.66%)、肺炎克雷伯菌(8.94%)。大肠埃希菌、肺炎克雷伯菌中ESBLs的检出率为分别为68.12%、41.03%,金黄色葡萄球菌中MRSA的检出率为91.95%。
大肠埃希菌对亚胺培南的耐药率为1.62%,对美罗培南的耐药率达到了5%；对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为17%、16%,对头孢他啶、头孢噻肟、头孢吡肟的耐药率均超过了75%；对头孢西丁的耐药率为26%,对阿卡米星仍保持较高的敏感性,耐药率仅为15%,对左氧氟沙星的耐药率为68%。铜绿假单胞菌对亚胺培南、美罗培南的耐药率分别为36%、46%；对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为27%、44%；对头孢他啶、头孢吡肟的耐药率分别为55%、68%,对阿卡米星的耐药率为14%,对左氧氟沙星的耐药率为50%。金黄色葡萄球菌对万古霉素的耐药率为0.22%、对呋喃妥因、复方新诺明、利福平、四环素、庆大霉素的耐药率分别为25%、40%、74%、76%、89%。鲍曼复合醋酸钙不动杆菌对亚胺培南、美罗培南的耐药率分别为73%、70%,对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为62%、73%,对头孢他啶、阿卡米星、左氧氟沙星的耐药率分别为84%、69%、74%。肺炎克雷伯菌对亚胺培南、美罗培南的耐药率分别为4%、11%,对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为41%、31%。
结论：我院2010年主要分离的细菌中,大肠埃希菌居第1位,其中ESBLs的检出率高达68.12%,对多种抗生素的耐药率均较高,并且出现了多重耐药菌株,给临床治疗带来较大的困难。目前,我院在治疗大肠埃希菌引起的感染时,抗生素的选择压力较大,成为一个亟待解决的问题。另外,铜绿假单胞菌、金黄色葡萄球菌、鲍曼复合醋酸钙不动杆菌、肺炎克雷伯菌的耐药状况同样不容乐观。
3实验研究
目的：通过研究痰热清注射液对产ESBLs大肠埃希菌超广谱β-内酰胺酶的影响,探讨痰热清对产ESBLs大肠埃希菌的耐药性产生影响的机制,为解决当前严峻的细菌耐药性问题提供可能的途径,也为进一步研究中药影响细菌耐药性的机制打下基础。
方法：取来源于临床,经全自动微生物鉴定和药敏分析系统(VITEK-32)进行鉴定和表型筛选的产ESBLs大肠埃希菌。采用试管2倍稀释法测定痰热清注射液对产ESBLs大肠埃希菌的MIC。采用纸片扩散法测定3个不同浓度的痰热清(痰热清1组、痰热清2组、痰热清3组)作用于产ESBLs大肠埃希菌后的药敏实验抑菌圈直径,以及经舒巴坦作用后(阳性组)和不经任何药物作用(阴性组)的耐药菌药敏实验的抑菌圈直径,并用分光光度法测定以上各组耐药菌的ESBLs活性；痰热清的浓度均选择低于其MIC的浓度。
结果：痰热清注射液对10株产ESBLs的大肠埃希菌的MIC为31.25μl/ml-125μl/ml。其中痰热清对菌株1、菌株2、菌株5、菌株6、菌株8、菌株9的MIC为62.5μl/ml。选取以上6株菌行药敏实验及ESBLs活性的测定实验。
经痰热清作用的菌株1、6、8,其头孢他啶、头孢噻肟、头孢哌酮的抑菌圈直径与阴性组比均具有统计学差异(P<0.05),菌株1、6、8对3种抗生素的敏感性均增强；经痰热清作用的菌株5,其头孢噻肟、头孢哌酮的抑菌圈直径与阴性组比具有统计学差异(P<0.05),菌株5对头孢噻肟、头孢哌酮的敏感性增强；经痰热清作用的菌株9,其头孢他啶的抑菌圈直径与阴性组比具有统计学差异(P<0.05),菌株9对头孢他啶的敏感性增强；经痰热清作用的菌株2,其3种抗生素的抑菌圈直径与阴性组比均无统计学差异(P<0.05),菌株2对3种抗生素的敏感性均未增强。
经痰热清作用的菌株1、5、6、9的ESBLs活性降低,与阴性组比均具有统计学差异(P<0.05)；经痰热清作用的菌株2、8的ESBLs活性未降低,与阴性组比均无统计学差异(P<0.05)。
结论：痰热清注射液对某些产ESBLs大肠埃希菌的ESBLs活性具有抑制作用,使其对某些抗生素的敏感性增强；痰热清对某些耐药菌的ESBLs活性无抑制作用,也不能使其对抗生素的敏感性增强；痰热清可能对不同的ESBLs的活性具有不同的影响；痰热清对某些耐药菌的ESBLs活性无抑制作用,但能使其对某些抗生素的敏感性增强,那么痰热清可能存在其他使耐药菌对抗生素敏感性增强的机制。
The Escherichia coli (E. coli) was the most common community acquired and hospital acquired pathogen. Among them, the infection caused by the extended-spectrum beta-lactamase (ESBLs) producing E. coli took the first place. ESBLs producing E. coli can hydrolyze penicillin, and the first, second, third generation and part of the fourth generation cephalosporin. Part of the strains can also resist aminoglycoside and fluoroquinolones antibiotics. So the infection caused by it was treated by less antibiotics, and the effect was often not ideal which increased mortality. This made the treatment difficult, made treatment fee increase, and also brought heavier social economic burden.
It was reported that some formulas had certain antibacterial effect on some bacteria in vivo, especially achieved good curative effect in the therapy of some drug-resistant bacteria infection diseases. And some Chinese medicine had stronger antimicrobial effect on some drug-resistant bacteria. So it is possible to give method for the current grim drug-resistant bacteria problems by further research on antibacterial effect on Chinese medicine.
This paper mainly included literature review, monitoring drug resistance of main bacteria in Dongfang hospital in 2010 and experimental research.
1 Literature review
The literature review introduced the research progress of traditional Chinese medicine antibacterial function, Tanreqing, and E. coli producing ESBLs.
2 Monitoring drug resistance of main bacteria in Dongfang hospital in 2010 Objective:To investigate the detection rate of main bacteria and the drug resistance of bacteria to antibiotics in Dongfang hospital of Beijing university of Chinese medicine in 2010.
Methods:According to certain regulations, to isolate and culture bacteria. according to CLSI,to identify and do drug susceptibility test by VITEK-32.
Results:From January to December of 2010,3489 strains were isolated in Dongfang hospital, the top five respectively were:E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter calcoaceticus-baumanii complex and Klebsiella pneumonia, and the detection rates were 17.71%,17.25%,12.81%, 10.66%,8.94% respectively. The detection rates of ESBLs producing E. coli and ESBLs producing Klebsiella pneumoniae respectively were 68.12% and 41.03%, and the rate of MRSA was 91.95%.
The resistance rate of E.coli to imipenem was 1.62% and that of E.coli to meropenem was 5%. The resistanc rates of E. coli to piperacillin/tazobactam and cefoperazone/sulbactam respectively were 17% and 16%. To ceftazidime, cefota-xime and cefepime, the rates were more than 75%. To cefoxitin, the rate was 26%. It remained high sensitive to amikacin with only 15% of antimicrobial resistance. The rate to Levof loxacin was 68%. The resistance rates of Pseudomonas aeruginosa to imipenem and meropenem respectively were 36% and 46%. The rates to piperacillin/tazobactam and cefoperazone/sulbactam were 27%,44% respecttively. The rates to ceftazidime, cefepime were 55% and 68% respectively, to amikacin was 14% and to levof loxacin was 50%. The resistance rate of Staphylococcus aureus to vancomycin was 0.22%, to nitrofurantoin, cotrimoxazole, rifampin, tetracycline, gentamicin were 25%,40%,74%,76% and 89% respectively. The resistance rates of Acinetobacter calcoaceticus-baumanii complex to imipenem and meropenem were 73%,70% respectively, to piperacillin/tazobactam and cefoperazone/sulbactam were 62%,73% respectively, to ceftazidime was 84%, to amikacin was 69%, and to levof loxacin was 74%. The resistance rates of Klebsiel la pneumoniae to imipenem and meropenem were 4%,11% respectively, to piperacillin/tazobactam and cefoperazone/sulbactam were 41%,31% respectively.
Conclusion:E. coli took the first place among the bacteria isolated from the hospital in 2010. The detection rate of ESBLs producing E.coli reached up to 68.12%, the resistance rates of E. coli to many antibiotics were higher on average and multiple drug-resistant strains appeared which brought greater difficulties in clinical treatment. The hospital had to face the problem that how to choose the antibiotics to treat the infections caused by E.coli. Furthermore, the situations in Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter calcoaceticus, and Klebsiella pneumoniae were not optimistic.
3 Experiment research
Objective:To study the impact of Tanreqing injection on ESBLs, discussing the mechanism of it. It was the basic for further study to antibacterial mechanism of Chinese medicine, and giving possible method for the current grim drug-resistant bacteria problems.
Methods:To take ESBLs producing E.coli from the clinical laboratory which identified by VITEK-32. To adopt two-folded dilution method to determine MIC of Tanreqing injection to E.coli producing ESBLs. To measure inhibition zone diameters of Tanreqing injection with different concentrations effecting on E. coli producing ESBLs by disc diffusion method. To use spectrophotometry to determine the ESBLs activity of E.coli affected by Tanreqing.
Results:The MIC of Tanreqing to 10 ESBLs producing E.coli strains were 31.25μl/ml-125μl/ml. The MIC of Tanreqing to strains 1,2,5,6,8 and 9 were 62.5μl/ml. To select the six strains to do drug sensitive test and determine the ESBLs activity.
Affected by Tanreqing, the inhibition zone diameters of ceftazidime, cefoperazone, cefotaxime of strains 1,6 and 8 were increased and their antibiotics sensitivity were enhanced, statistically significantly (P<0.05). The inhibition zone diameters of cefotaxime and cefoperazone of strain 5 were increased, and its sensitivity to cefotaxime and cefoperazone were enhanced, statistically significantly (P<0.05). The inhibition zone diameter of ceftazidime of strain 9 was increased, and its sensitivity to ceftazidime was enhanced, statistically significantly (P<0.05). The inhibition zone diameters of three kinds antibiotics of strains 2 and 8 were not increased and their sensitivity were not enhanced (P>0.05).
Affected by Tanreqing, ESBLs activity of strainsl,5,6 and 9 decreased statistically significantly(P<0.05), ESBLs activity of the strains 2,8 did not reduce (P>0.05).
Conclusion:Tanreqing inhibited the ESBLs activity of some E. coli strains and enhanced their sensitivity to some antibiotics; Tanreqing had no inhibition on the ESBLs activity of some E. coli strains, and also did not strengthen their sensitivity to antibiotics; Tanreqing may had different impact on different ESBLs of E. coli. Tanreqing had no impact on ESBLs activity of some strains, but increased their sensitivity to some antibiotics. There may be other mechanism for Tanreqing to strengthen antibiotics sensitivity of drug-resistant strains.
许多研究报道某些中药方剂在体内具有良好的抗菌作用,尤其是在治疗或联合抗生素治疗耐药菌感染的疾病上,取得了较好的临床疗效。而且某些中药在体外对临床常见耐药菌具有较强的抗菌作用,因此深入研究中药对耐药菌耐药性的影响,有望为解决目前严峻的细菌耐药问题提供新的途径。
本论文主要包括文献综述、北京中医药大学东方医院2010年主要细菌耐药性监测、实验研究3部分。
1文献综述
分为3部分,分别介绍了中药抗菌作用的研究进展、痰热清抗感染作用的研究进展以及产ESBLs大肠埃希菌的研究进展。
2北京中医药大学东方医院2010年主要病原菌耐药性监测
目的：了解2010年北京中医药大学东方医院主要细菌的检出率及对抗生素的耐药状况。
方法：参照《全国临床检验操作规程》第2版获取细菌标本。参照CLSI推荐的方法,采用全自动微生物鉴定和药敏分析系统VITEK-32进行细菌鉴定以及药敏实验。
结果：2010年1月至12月东方医院共分离细菌3489株,占前5位的细菌及其比例分别是：大肠埃希菌(17.71%)、铜绿假单胞菌(17.25%)、金黄色葡萄球菌(12.81%)、鲍曼复合醋酸钙不动杆菌(10.66%)、肺炎克雷伯菌(8.94%)。大肠埃希菌、肺炎克雷伯菌中ESBLs的检出率为分别为68.12%、41.03%,金黄色葡萄球菌中MRSA的检出率为91.95%。
大肠埃希菌对亚胺培南的耐药率为1.62%,对美罗培南的耐药率达到了5%；对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为17%、16%,对头孢他啶、头孢噻肟、头孢吡肟的耐药率均超过了75%；对头孢西丁的耐药率为26%,对阿卡米星仍保持较高的敏感性,耐药率仅为15%,对左氧氟沙星的耐药率为68%。铜绿假单胞菌对亚胺培南、美罗培南的耐药率分别为36%、46%；对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为27%、44%；对头孢他啶、头孢吡肟的耐药率分别为55%、68%,对阿卡米星的耐药率为14%,对左氧氟沙星的耐药率为50%。金黄色葡萄球菌对万古霉素的耐药率为0.22%、对呋喃妥因、复方新诺明、利福平、四环素、庆大霉素的耐药率分别为25%、40%、74%、76%、89%。鲍曼复合醋酸钙不动杆菌对亚胺培南、美罗培南的耐药率分别为73%、70%,对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为62%、73%,对头孢他啶、阿卡米星、左氧氟沙星的耐药率分别为84%、69%、74%。肺炎克雷伯菌对亚胺培南、美罗培南的耐药率分别为4%、11%,对哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率分别为41%、31%。
结论：我院2010年主要分离的细菌中,大肠埃希菌居第1位,其中ESBLs的检出率高达68.12%,对多种抗生素的耐药率均较高,并且出现了多重耐药菌株,给临床治疗带来较大的困难。目前,我院在治疗大肠埃希菌引起的感染时,抗生素的选择压力较大,成为一个亟待解决的问题。另外,铜绿假单胞菌、金黄色葡萄球菌、鲍曼复合醋酸钙不动杆菌、肺炎克雷伯菌的耐药状况同样不容乐观。
3实验研究
目的：通过研究痰热清注射液对产ESBLs大肠埃希菌超广谱β-内酰胺酶的影响,探讨痰热清对产ESBLs大肠埃希菌的耐药性产生影响的机制,为解决当前严峻的细菌耐药性问题提供可能的途径,也为进一步研究中药影响细菌耐药性的机制打下基础。
方法：取来源于临床,经全自动微生物鉴定和药敏分析系统(VITEK-32)进行鉴定和表型筛选的产ESBLs大肠埃希菌。采用试管2倍稀释法测定痰热清注射液对产ESBLs大肠埃希菌的MIC。采用纸片扩散法测定3个不同浓度的痰热清(痰热清1组、痰热清2组、痰热清3组)作用于产ESBLs大肠埃希菌后的药敏实验抑菌圈直径,以及经舒巴坦作用后(阳性组)和不经任何药物作用(阴性组)的耐药菌药敏实验的抑菌圈直径,并用分光光度法测定以上各组耐药菌的ESBLs活性；痰热清的浓度均选择低于其MIC的浓度。
结果：痰热清注射液对10株产ESBLs的大肠埃希菌的MIC为31.25μl/ml-125μl/ml。其中痰热清对菌株1、菌株2、菌株5、菌株6、菌株8、菌株9的MIC为62.5μl/ml。选取以上6株菌行药敏实验及ESBLs活性的测定实验。
经痰热清作用的菌株1、6、8,其头孢他啶、头孢噻肟、头孢哌酮的抑菌圈直径与阴性组比均具有统计学差异(P<0.05),菌株1、6、8对3种抗生素的敏感性均增强；经痰热清作用的菌株5,其头孢噻肟、头孢哌酮的抑菌圈直径与阴性组比具有统计学差异(P<0.05),菌株5对头孢噻肟、头孢哌酮的敏感性增强；经痰热清作用的菌株9,其头孢他啶的抑菌圈直径与阴性组比具有统计学差异(P<0.05),菌株9对头孢他啶的敏感性增强；经痰热清作用的菌株2,其3种抗生素的抑菌圈直径与阴性组比均无统计学差异(P<0.05),菌株2对3种抗生素的敏感性均未增强。
经痰热清作用的菌株1、5、6、9的ESBLs活性降低,与阴性组比均具有统计学差异(P<0.05)；经痰热清作用的菌株2、8的ESBLs活性未降低,与阴性组比均无统计学差异(P<0.05)。
结论：痰热清注射液对某些产ESBLs大肠埃希菌的ESBLs活性具有抑制作用,使其对某些抗生素的敏感性增强；痰热清对某些耐药菌的ESBLs活性无抑制作用,也不能使其对抗生素的敏感性增强；痰热清可能对不同的ESBLs的活性具有不同的影响；痰热清对某些耐药菌的ESBLs活性无抑制作用,但能使其对某些抗生素的敏感性增强,那么痰热清可能存在其他使耐药菌对抗生素敏感性增强的机制。
The Escherichia coli (E. coli) was the most common community acquired and hospital acquired pathogen. Among them, the infection caused by the extended-spectrum beta-lactamase (ESBLs) producing E. coli took the first place. ESBLs producing E. coli can hydrolyze penicillin, and the first, second, third generation and part of the fourth generation cephalosporin. Part of the strains can also resist aminoglycoside and fluoroquinolones antibiotics. So the infection caused by it was treated by less antibiotics, and the effect was often not ideal which increased mortality. This made the treatment difficult, made treatment fee increase, and also brought heavier social economic burden.
It was reported that some formulas had certain antibacterial effect on some bacteria in vivo, especially achieved good curative effect in the therapy of some drug-resistant bacteria infection diseases. And some Chinese medicine had stronger antimicrobial effect on some drug-resistant bacteria. So it is possible to give method for the current grim drug-resistant bacteria problems by further research on antibacterial effect on Chinese medicine.
This paper mainly included literature review, monitoring drug resistance of main bacteria in Dongfang hospital in 2010 and experimental research.
1 Literature review
The literature review introduced the research progress of traditional Chinese medicine antibacterial function, Tanreqing, and E. coli producing ESBLs.
2 Monitoring drug resistance of main bacteria in Dongfang hospital in 2010 Objective:To investigate the detection rate of main bacteria and the drug resistance of bacteria to antibiotics in Dongfang hospital of Beijing university of Chinese medicine in 2010.
Methods:According to certain regulations, to isolate and culture bacteria. according to CLSI,to identify and do drug susceptibility test by VITEK-32.
Results:From January to December of 2010,3489 strains were isolated in Dongfang hospital, the top five respectively were:E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter calcoaceticus-baumanii complex and Klebsiella pneumonia, and the detection rates were 17.71%,17.25%,12.81%, 10.66%,8.94% respectively. The detection rates of ESBLs producing E. coli and ESBLs producing Klebsiella pneumoniae respectively were 68.12% and 41.03%, and the rate of MRSA was 91.95%.
The resistance rate of E.coli to imipenem was 1.62% and that of E.coli to meropenem was 5%. The resistanc rates of E. coli to piperacillin/tazobactam and cefoperazone/sulbactam respectively were 17% and 16%. To ceftazidime, cefota-xime and cefepime, the rates were more than 75%. To cefoxitin, the rate was 26%. It remained high sensitive to amikacin with only 15% of antimicrobial resistance. The rate to Levof loxacin was 68%. The resistance rates of Pseudomonas aeruginosa to imipenem and meropenem respectively were 36% and 46%. The rates to piperacillin/tazobactam and cefoperazone/sulbactam were 27%,44% respecttively. The rates to ceftazidime, cefepime were 55% and 68% respectively, to amikacin was 14% and to levof loxacin was 50%. The resistance rate of Staphylococcus aureus to vancomycin was 0.22%, to nitrofurantoin, cotrimoxazole, rifampin, tetracycline, gentamicin were 25%,40%,74%,76% and 89% respectively. The resistance rates of Acinetobacter calcoaceticus-baumanii complex to imipenem and meropenem were 73%,70% respectively, to piperacillin/tazobactam and cefoperazone/sulbactam were 62%,73% respectively, to ceftazidime was 84%, to amikacin was 69%, and to levof loxacin was 74%. The resistance rates of Klebsiel la pneumoniae to imipenem and meropenem were 4%,11% respectively, to piperacillin/tazobactam and cefoperazone/sulbactam were 41%,31% respectively.
Conclusion:E. coli took the first place among the bacteria isolated from the hospital in 2010. The detection rate of ESBLs producing E.coli reached up to 68.12%, the resistance rates of E. coli to many antibiotics were higher on average and multiple drug-resistant strains appeared which brought greater difficulties in clinical treatment. The hospital had to face the problem that how to choose the antibiotics to treat the infections caused by E.coli. Furthermore, the situations in Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter calcoaceticus, and Klebsiella pneumoniae were not optimistic.
3 Experiment research
Objective:To study the impact of Tanreqing injection on ESBLs, discussing the mechanism of it. It was the basic for further study to antibacterial mechanism of Chinese medicine, and giving possible method for the current grim drug-resistant bacteria problems.
Methods:To take ESBLs producing E.coli from the clinical laboratory which identified by VITEK-32. To adopt two-folded dilution method to determine MIC of Tanreqing injection to E.coli producing ESBLs. To measure inhibition zone diameters of Tanreqing injection with different concentrations effecting on E. coli producing ESBLs by disc diffusion method. To use spectrophotometry to determine the ESBLs activity of E.coli affected by Tanreqing.
Results:The MIC of Tanreqing to 10 ESBLs producing E.coli strains were 31.25μl/ml-125μl/ml. The MIC of Tanreqing to strains 1,2,5,6,8 and 9 were 62.5μl/ml. To select the six strains to do drug sensitive test and determine the ESBLs activity.
Affected by Tanreqing, the inhibition zone diameters of ceftazidime, cefoperazone, cefotaxime of strains 1,6 and 8 were increased and their antibiotics sensitivity were enhanced, statistically significantly (P<0.05). The inhibition zone diameters of cefotaxime and cefoperazone of strain 5 were increased, and its sensitivity to cefotaxime and cefoperazone were enhanced, statistically significantly (P<0.05). The inhibition zone diameter of ceftazidime of strain 9 was increased, and its sensitivity to ceftazidime was enhanced, statistically significantly (P<0.05). The inhibition zone diameters of three kinds antibiotics of strains 2 and 8 were not increased and their sensitivity were not enhanced (P>0.05).
Affected by Tanreqing, ESBLs activity of strainsl,5,6 and 9 decreased statistically significantly(P<0.05), ESBLs activity of the strains 2,8 did not reduce (P>0.05).
Conclusion:Tanreqing inhibited the ESBLs activity of some E. coli strains and enhanced their sensitivity to some antibiotics; Tanreqing had no inhibition on the ESBLs activity of some E. coli strains, and also did not strengthen their sensitivity to antibiotics; Tanreqing may had different impact on different ESBLs of E. coli. Tanreqing had no impact on ESBLs activity of some strains, but increased their sensitivity to some antibiotics. There may be other mechanism for Tanreqing to strengthen antibiotics sensitivity of drug-resistant strains.
引文
[1]刘平,叶惠芬,陈惠玲.5种中药对产酶菌的抑菌作用[J].中国微生态学杂志,2006,189(1)：39.
[2]周雪宁,权志博,王雷.五倍子等三种中药体外抗产ESBLs大肠埃希菌研究及其探讨[J].陕西中医学院学报,2009,32(5)：80-81.
[3]栾耀芳,张凤花,吴国英.黄芩等8种中药对产β-内酰胺酶大肠埃希菌的敏感性研究[J].山东中医杂志2005,24(10)：629-631.
[4]冷会勇,闫志勇,王斌.十八种中药制剂对多重耐药鲍曼不动杆菌体外抗菌作用的研究[J].中外医疗,2010,17：132.
[5]李仲兴,王秀华,赵建宏,等.五倍子等14种中药对112株金黄色葡萄球菌的抗菌活性 观察,2007,14(10)：35-37.
[6]李建志,刘旭红,杨丽珍,王亚贤.11种中草药抗菌作用实验研究[J].中医药信息,2009,26(3)：82-83.
[7]YakubuM Bello, OdamaLE, Nandita B De. Studies on theAntibacteri-alActivity of the Extract of Stachytarpheta angustifolia [J]. Journal of NanjingMedical university.2003,17(3):116.
[8]袁靖,张淑华.双黄连口服液对产超广谱β-内酰胺酶菌的体外活性研究[J].四川生理科学杂志,2001,23(3)：131.
[9]陈双璐,陆国金.注射液双黄连与几种抗生素联合体外抑菌活性的研究[J].中国现代应用药学杂志,1998,8,15(4)：58-60.
[10]林彬,李仲昆,黄惠珍,等.黄连粉针与4种抗生素的伍用[J].中国药房,2000,9(4)：171.
[11]李仲昆,林杉,李海蜀,等.双黄连粉针与4种抗生素伍用的体外最小抑菌浓度研究[J].中成药,1999,21(3)：137-139.
[12]李东,黄继华,张淑华.注射用清开灵冻干粉体外抗菌活性研究[J].四川生理科学杂志2008,30(4)：164-166.
[13]高益民,王忠山.对痰热清注射液临床药学初步评价[J].首都医药,2004,4(12)：44-46.
[14]李建农,包定元,包旭,等.解热毒注射液抗菌作用的实验研究[J].四川生理科学杂志,2000,22(4)：44.
[15]陈林娜,周立勤,王汉敏,等.中药对临床耐药菌株的体外抑菌试验观察[J].中华医院感染学杂志,2005,15(1)：118-120.
[16]包旭,张淑华,欧真蓉.黄心分散片抗菌作用的研究[J].中药药理与临床,2001,17(5)：39.
[17]董艳,白雪峰,石学魁,等.五味消毒饮对金黄色葡萄球菌凝固酶活性的影响[J].时珍国医国药,2001,12(9)：790-791.
[18]雷连成,韩文瑜,乔红伟.大肠杆菌耐药性中药抑制剂的初步研究[J].吉林农业大学学报,2003,25(4)：429-433.
[19]芦亚君,程宁.3种中药方剂逆转大肠杆菌耐药性的实验观察[J].西北药学杂志,2007,22(6)：309-310.
[20]贾云鹏,程宁.中药对大肠埃希菌抗生素耐药性逆转作用的实验研究[J].陕西中医,2009,30(3)：366-367.
[21]黄通旺,杨灏强,庞珊.抑制p-内酰胺酶的中草药的筛选研究[J].汕头大学学报,2000,15(2)：46-49.
[22]杜银忠.3种中药对产酶菌R质粒消除作用的研究[J].青海大学学报,2009,27(1)： 78-79.
[23]陈小英.大黄素对金黄色葡萄球菌抗生素耐药质粒的消除作用[J].南京药学院学报,1985(16)2：48-51.
[24]祁汝峰,黄瑞,祁小飞.中西药消除耐药质粒pRST98的研究[J].中国血液流变学杂志,2004,14(1)：46-47.
[25]雷连成,韩文瑜,段艳.大肠杆菌耐药性抑制作用机制的初步研究[J].中国兽药杂志,2004,38(2)：18-21.
[26]李仝,胡凯文,陈信义,等.浙贝母对呼吸系统耐药金黄色葡萄球菌逆转作用的临床研究.北京中医药大学学报,2001,9,24(5)：51-52.
[1]刘建梅,陈强,李岚,等.痰热清注射液佐治小儿呼吸道感染60例[J].实用儿科临床杂志,2005,20(10)：1040.
[2]陈淑娟.痰热清联合西药治疗老年慢性支气管炎急性发作期的疗效观察[J].辽宁中医药大学学报2009,11(8)：154-155.
[3]吴晓明.痰热清注射液治疗慢性阻塞性肺疾病急性加重期例[J].中国中医急症2010,19(4)：659.
[4]李国勤,边永君.痰热清结合抗生素治疗急性细菌性肺炎50例[J].中国新药杂志,2008,17(6)：509-511.
[5]杨罡.痰热清注射液治疗社区获得性肺炎疗效研究[J].时珍国医国药,2007,18(8)：2017-2018.
[6]曹雪松,林治范,王玉昆.痰热清治疗肺结核124例疗效观察[J].中国当代医药2009,16(10)：146.
[7]郭海彬,柴世磊.痰热清注射液治疗肺脓肿50例[J].2009,29(8)：815-816.
[8]石莹.痰热清注射液治疗病毒性上呼吸道感染高热40例[J].浙江中医杂志,2009,44(8)：621.
[9]甲型H1N1流感诊疗方案[EB/OL].http://www.chinac2dc.Net.cn/n272442/n272530/ n273736/n273781/n4624704/n4624714/3107.html,2009.
[10]李刚.痰热清注射液联合奥司他韦治疗甲型H1N1流感疗效观察[J].中国中医急症,2010,19(10)：1681-1682.
[11]陈强,石正禄.痰热清注射液治疗病毒性肺炎疗效观察[J].中国中医急症,2008,17(12)：689.
[12]谭正炳.痰热清联合头孢噻肟钠治疗肝硬化并自发性腹膜炎临床体会[J].中国中医急症,2008,17(11)：1613.
[13]李小梅,宋盛青.痰热清注射液治疗急性胆囊炎38例[J].中医研究,2007(20)8：39-41.
[14]李克明,鲁厚胜.痰热清注射液治疗急性泌尿系统感染疗效观察[J].中国中医急症,2007,16(5)：542.
[15]刘启如,方平安.痰热清注射液治疗流行性乙型脑炎临床观察[J].中国中医急2008,(17)：1201.
[16]黄章.痰热清联合利巴韦林治疗儿童手足口病的临床分析[J].中外医疗,2009,27：84-85.
[17]杨军,魏敏.痰热清注射液治疗麻疹疗效观察[J].西南国防医药,2008,(18)5：693-
[18]谭正炳.痰热清注射液治疗登革热疗效观察[J].中外医疗,2008 N0.23：75.
[19]杜晓华,张力燕.痰热清注射液对AECOPD患者肺功能和炎症因子的影响[J],中国中医急症,2009,18(12)：1952.
[20]罗光伟,孙洁民,毛先明.痰热清注射液对痰热壅肺型COPD急性加重期C反应蛋白的影响[J].中国中医急症,2009,18(12)：1954-1955.
[21]龚国良,李欣.痰热清治疗慢性阻塞性肺疾病急性加重期的临床疗效及细胞因子水平的研究[J].中国中药杂志,2009,34(1)：104-106.
[22]廖振荣.痰热清注射液对COPD急性发作患者血清IL-17和IL-8表达的影响[J].医学研究杂志,2009,38(7)：103-105.
[23]余应喜,刘景仑.痰热清注射液对ICU呼吸机相关性肺炎患者CRP、IL-6和TNF-a的调节作用[J].中国中医急症2009,18(2)：184-185.
[24]胡庆全,痰热清注射液对老年慢性支气管炎急性发作患者体液免疫及肿瘤坏死因子α浓度的影响[J].中成药,2008,3(10)：1415-1417.
[25]张静,王晓红,杨俊泉,胡万宁,张瑞娟.痰热清注射液对血浆IL-6及ACE影响及防治放射性肺炎疗效观察[J].使用实用预防医学,2009(16)5：1537-1539.
[26]王晓红.痰热清注射液对血浆内皮素-1的影响及防治放射性肺损伤的疗效观察[J].中国煤炭工业学杂志,2008,11(12)：1823-1825.
[27]杨晓刚,郭德和,何进喜.心脏瓣膜置换术患者围手术期细胞因子TNF-a, IL-6的变化及痰热清注射液对其的影响[J].第四军医大学学报,2009,30(21)：2379-2381.
[28]黄登鹏,彭卫平,陈少武,伍华梅.痰热清注射液治疗重症急性胰腺炎抗炎作用观察[J].中国中医急症,2005,14(2)：117.
[29]牛旭艳,王甫,张春晶.痰热清注射液对FMI感染HEK-293T细胞NF-KB转录活性及TNF-a产生影响的研究[J].中华中医药杂志(原中国医药学报)2008增刊：149-152.
[30]郑金粟,顾立刚.痰热清注射液对流感病毒FM1感染小鼠抗病毒作用的研究[J].中华中医药杂志(原中国医药学报),2009,24(7)：851-854.
[31]刘红菊,张玉.痰热清的抗氧化作用及对急性肺损伤的抑制作用研究[J].中国医院药学杂志,2009,29(19)：1607-1610.
[32]孔祥鸣,吴稚冰.痰热清注射液对急性放射性肺炎大鼠血清TGF-β1水平及肺病理学改变的影响[J].实用中西医结合临床2008,8(4)：85-86.
[33]刘德红,邓哲.痰热清注射液对脓毒症大鼠核因子-κB活性及生存率的影响[J].实用医学杂志2008,24(13)：2208-2210.
[34]徐晓月,等.3种痰热清胶囊小鼠体内抗流感病毒作用的比较[J].抗感染药学2005,5(3)：142-144.
[1]Kumarasamy K K, Toleman M A, Walsh T R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK:a molecular, biological, and epidemiologicalstudy[J]. Lancet Infect Dis,2010,10(9):597-602.
[2]Boseley S. Are you ready for a world without antibiotics? [EB/OL]. Guardian, co. uk,2010-8-11, http://www.guardian.co.uk/society/2010/aug/12/the end of antibiotics health infections.
[3]Donald G, Mcneil J. Antibiotic-resistant bacteria moving fromsouth Asia to U.S. [N]. New York Times,2010,8,11.
[4]戴德银,康晓曦,张燕.“超级细菌”现状及防治对策[J].现代临床医学,2010,36(6)：414.
[5]Patermn DL, Bonomo RA. Extended-spectrum beta-lactamases:a clinical update. Clin MicrobiolRev,2005,18 (4):657-686.
[6]Hadziyannis E, Tuohy M, ThomasL, atel. Screening methods for detection of extende-spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella oxytoca clinical isolates [J]. DiagnMicrobiolInfectDisease,2000,36:113-117.
[7]Ho PL, TsangDN, QueTL, atel. Comparison of screening methodsfor detection of extended-spectrum beta-lactamases and their prevalence among Escherichia coli and Klebsiella species in HongKong[J]. APM ITS,2000,108:237-240.
[8]张秀珍,胡云建,艾小曼,许宏涛.Mohnarin 2006-2007年度报告：华北地区细菌耐药监测[J].中国抗生素杂志,2008,33(10)：616-621.
[9]陈茶,黄彬,张文.产ESBLs大肠埃希菌及肺炎克雷伯菌的基因分型研究[J].广东医 学,2006,27(5)：686-687.
[10]胥飚,曹何,余显书.肠杆菌科产超广谱β-内酰胺酶菌株的耐药性及基因型分析[J].重庆医科大学学报,2004,29(6)：781-783.
[11]胡云建,俞云松,张秀珍,等.产超广谱β-内酰胺酶细菌的分子流行病学研究[J].中华医院感染学杂志,2004,14(3)：241-244.
[12]庞众多,任君慧,陈永红.产超广谱p-内酰胺酶大肠埃希菌的检测[J].中国卫生检验杂志,2009,19(3)：619-620.
[13]叶素娟,杨青,俞云松.2005年中国CHINET大肠埃希菌和肺炎克雷伯菌耐药性分析[J].中国感染与化疗杂志,2007,7(4)：283-286.
[14]卓超,苏丹虹,朱德妹.2007年中国CHINET大肠埃希菌和肺炎克雷伯菌耐药性分析[J].中国感染与化疗杂志,2009,9(3)：185-191.
[15]汪复,朱德妹,胡付品,等.2009年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2010,10(5)：325-334.
[16]张珍珍,吴俊伟,杨卫军.大肠埃希氏菌对β-内酰胺类抗生素耐药机制的研究进展[J].中国兽药杂志,2008,42(7)：36-40.
[17]吴佳丽,顾洪琴,俞云松,等.杭州市产超广谱p-内酰胺酶菌株耐药性和基因型分布研究[J].浙江医学,2005,27(6)：401-403.
[18]季淑娟,陈亚岗,俞云松,等.浙江省产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的基因分型[J].中华传染病杂志,2005,23(2)：75-79.
[19]季淑娟,顾怡明,谭文涛,等.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因型研究[J].中华检验医学杂志,2004,27(9)：590-593.
[20]俞云松.超广谱β-内酰胺酶研究概况[J].中国抗生素杂志,28(12)：712.
[21]王华丽.大肠埃希菌耐药机制研究及进展[J].国外医药抗生素分册2005,26(3)：133-136.
[22]BonnetR. Growing Group of Extended-spectrum β-lactamases:the CTX-M Enzymes [J]. AntimicrobialAgentsChemotherapy,2004,48(1):1-14.
[23]陆坚,唐英春,张扣兴,等.CTX-M-14型超广谱β-内酰胺酶基因的定点突变研究[J].中华微生物学和免疫学杂志,2003,23(10)：800-804.
[24]李虹玲,刘文恩.SHV型超广谱β-内酰胺酶的研究进展[J].实用预防医学,2007,14(1)：253-255.
[25]Pena. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect,2006,12 (3):279-284.
[26]吕晓菊.肠杆菌科产超广谱β内酰胺酶细菌耐药性研究进展[J].国外医学抗生素分册,2001,22(2)：66-69.
[27]陈升汶,卢月梅,张阮章,等.大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因分型研究[J].中华检验医学杂志,2006,29(2)：166-167.
[28]段建春,吕晓菊,赵燕,等.产ESBLs肠杆菌科细菌对氨基糖苷类抗生素耐药机制研究[J].中国抗生素杂志,2005,30(9)：555-558.
[29]Delonetcr, Schiller N L. Characterization of an in Vitro selected amoxicillin-resistant strain of Helicobacterpylori[J]. Antimicrob Agents Chemother, 2000,44 (11):3368-3373.
[30]陈亚岗,俞云松,周伟琳,等.浙江省产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌流行情况及耐药性[J],中华传染病学杂志,2000,18：263.
[1]刘文静,张小江,杨文航.2008年北京协和医院细菌耐药性监测结果分析[J].中国感染与化疗杂志,2010,10(4)：290-295.
[2]汪复,朱德妹,胡付品.2009年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志2010,10(5)：325-334.
[3]陈贤华,梁思群.2003-2007年大肠埃希菌耐药性监测分析[J].现代医药卫生,2008,24(15)：2269-2270.
[4]高娅文,杨宇,吴悦陶.抗菌药物使用与产超广谱β-内酰胺酶的关系[J].中华医院感染学杂志,2009,19(20)：2763-2765.
[5]王淑峰,戎建荣.大肠埃希菌β-内酰胺酶基因分型与耐药性研究[J].中华医院感染学杂志,2009,19(17)：2236-2238.
[6]裴保香,郭绍来,王睿,等.大肠埃希菌耐药性与头孢菌素类用量变化的相关性分析[J].中华医院感染学杂志,2004,14(4)：373-376.
[7]Colodner R. Extended-spectrum beta-lactamases:a challenge for clinical microbiologist and infection control specialists[J]. Am J Infect Control, 2005,33 (2):104-107.
[8]MendelsonG, HaitV, Ben-IsraelJ, etal.Prevalence and risk factors of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniaein an Israeli long term care facility[J]. Eur J Clin Microbiol Infect Dis,2005,24(1):17-22.
[9]林庆安,赖国祥,黄梁浒,等.福州地区肺炎克雷伯氏菌和大肠埃希氏菌的药敏监测[J].中国抗生素杂志,2004,29(2)：79-81.
[10]罗燕萍,张秀菊,徐雅萍,等.产超广谱p-内酰胺酶肺炎克雷伯菌和大肠埃希菌的分布及其耐药性研究[J].中华医院感染学杂志,2006,16(1)：101-104.
[11]管希周,罗燕萍,刘又宁,等.高产AmpC酶肺炎克雷伯菌的临床报道[J].中华医院感染学杂志,2004,14(4)：461-464.
[12]王继东,周丽珍,宫玲玲,等.铜绿假单胞菌的多重耐药基因研究[J].中华医院感染学杂志,2006,16(3)：241-244.
[13]陈瑞,唐英春,朱家馨,等.耐亚胺培南铜绿假单胞菌的耐药性及分子流行病学研究[J].中华医院感染学杂志,2006,16(4)：371-373.
[1]贾云鹏,程宁.中药对大肠埃希菌抗生素耐药性逆转作用的实验研究[J].陕西中医,2009,30(3)：366-367.
[2]凌保东,谢勇恩,张翔,等.产ESBLs液化沙雷氏菌临床分离株的表型和基因型分析[J].中国抗生素杂志,2003,28(12)：741-743.
[3]闰淑雅,李家泰.革兰阴性杆菌中β-内酰胺酶催化水解头孢氨噻肟动力学[J].中国药理学报,1988,9：448-452.
[4]高益民,王忠山.对痰热清注射液临床药学初步评价[J].首都医药,2004,4(12)：44- 46.
[5]李显志译.细菌的耐药性.国外医药抗生素分册,1995,16(1)：30.
[6]王静,张淑文.中药逆转细菌耐药的研究进展[J].临床和实验医学志,2007,6(1)：153.
[7]黄通旺,杨撷强,庞珊.抑制β-内酰胺酶的中草药的筛选研究[J].汕头大学学报(自然科学版),2000,15(2)：200.
[8]黄通旺,杨撷强.庞珊.抑制β-内酰胺酶的中草药的筛选研究[J].汕头大学学报(自然科学版),2000,15(2)：200.
[9]杜军,李敏.产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌耐药性及基因型研究[J].中国抗生素杂志,2009,34(8)：512.
[10]郑为平,史伟峰.产超广谱β-内酰胺酶大肠埃希菌相关耐药基因研究[J].中华医院感染学杂志,2009,19(13)：1629-1630.
[11]Livermore DM. Beta-lactamases in laboratory and clinical resistance[J]. Clin Microbiol Rev,1995,8:557-584.
[12]张珍珍,吴俊伟,杨卫军.大肠埃希氏菌对β-内酰胺类抗生素耐药机制的研究进展[J].中国兽药杂志,2008,42(7)：36-40.
[13]BonnetR. Growing Group of Extended-spectrum β-lactamases:the CTX-MEnzymes [J].AntimicrobialAgentsChemotherapy,2004,48(1):1-14.
[14]陆坚,唐英春,张扣兴,等.CTX-M-14型超广谱β-内酰胺酶基因的定点突变研究[J].中华微生物学和免疫学杂志,2003,23(10)：800-804.
[15]陈民钧.细菌耐药性及其临床意义[J].中华外科杂志,1998,36(A00)：6-8.
[16]童明庆,刘根焰.细菌耐药与临床对策[J].临床检验及实验室设备,2005,6(2)：32-33.
[17]Nikaido H Outer membrane barrier as a mechanism of antimicrobial resistance Antimicrob Agents Chemother,1989,33:1831-1836.
[18]雷连成,韩文瑜,段艳.大肠杆菌耐药性抑制作用机制的初步研究[J].中国兽药杂志,2004,38(2)：18-21.
[19]Nishino K, Yamada J,Hirakawa H, et al. Roles of TolC-dependent multidrug transporters of Escherichia coli in resistance to β-lactams[J]. Antimicrob AgentsChemother,2003,47 (9):3030.
[20]李仝,胡凯文,陈信义,等.浙贝母对呼吸系统耐药金黄色葡萄球菌逆转作用的临床研究[J].北京中医药大学学报,2001,9,24(5)：51-52.
[21]王华丽.大肠埃希菌耐药机制研究及进展[J].国外医药抗生素分册2005,26(3)：133-136.
[22]雷连成,韩文瑜.大肠杆菌耐药性中药抑制剂的初步研究[J].吉林农业大学学报2003,25(4)：429-433.
[23]王本祥.现代中药药理学[M].天津：天津科学技术出版社,1997：1-2.
[2]周雪宁,权志博,王雷.五倍子等三种中药体外抗产ESBLs大肠埃希菌研究及其探讨[J].陕西中医学院学报,2009,32(5)：80-81.
[3]栾耀芳,张凤花,吴国英.黄芩等8种中药对产β-内酰胺酶大肠埃希菌的敏感性研究[J].山东中医杂志2005,24(10)：629-631.
[4]冷会勇,闫志勇,王斌.十八种中药制剂对多重耐药鲍曼不动杆菌体外抗菌作用的研究[J].中外医疗,2010,17：132.
[5]李仲兴,王秀华,赵建宏,等.五倍子等14种中药对112株金黄色葡萄球菌的抗菌活性 观察,2007,14(10)：35-37.
[6]李建志,刘旭红,杨丽珍,王亚贤.11种中草药抗菌作用实验研究[J].中医药信息,2009,26(3)：82-83.
[7]YakubuM Bello, OdamaLE, Nandita B De. Studies on theAntibacteri-alActivity of the Extract of Stachytarpheta angustifolia [J]. Journal of NanjingMedical university.2003,17(3):116.
[8]袁靖,张淑华.双黄连口服液对产超广谱β-内酰胺酶菌的体外活性研究[J].四川生理科学杂志,2001,23(3)：131.
[9]陈双璐,陆国金.注射液双黄连与几种抗生素联合体外抑菌活性的研究[J].中国现代应用药学杂志,1998,8,15(4)：58-60.
[10]林彬,李仲昆,黄惠珍,等.黄连粉针与4种抗生素的伍用[J].中国药房,2000,9(4)：171.
[11]李仲昆,林杉,李海蜀,等.双黄连粉针与4种抗生素伍用的体外最小抑菌浓度研究[J].中成药,1999,21(3)：137-139.
[12]李东,黄继华,张淑华.注射用清开灵冻干粉体外抗菌活性研究[J].四川生理科学杂志2008,30(4)：164-166.
[13]高益民,王忠山.对痰热清注射液临床药学初步评价[J].首都医药,2004,4(12)：44-46.
[14]李建农,包定元,包旭,等.解热毒注射液抗菌作用的实验研究[J].四川生理科学杂志,2000,22(4)：44.
[15]陈林娜,周立勤,王汉敏,等.中药对临床耐药菌株的体外抑菌试验观察[J].中华医院感染学杂志,2005,15(1)：118-120.
[16]包旭,张淑华,欧真蓉.黄心分散片抗菌作用的研究[J].中药药理与临床,2001,17(5)：39.
[17]董艳,白雪峰,石学魁,等.五味消毒饮对金黄色葡萄球菌凝固酶活性的影响[J].时珍国医国药,2001,12(9)：790-791.
[18]雷连成,韩文瑜,乔红伟.大肠杆菌耐药性中药抑制剂的初步研究[J].吉林农业大学学报,2003,25(4)：429-433.
[19]芦亚君,程宁.3种中药方剂逆转大肠杆菌耐药性的实验观察[J].西北药学杂志,2007,22(6)：309-310.
[20]贾云鹏,程宁.中药对大肠埃希菌抗生素耐药性逆转作用的实验研究[J].陕西中医,2009,30(3)：366-367.
[21]黄通旺,杨灏强,庞珊.抑制p-内酰胺酶的中草药的筛选研究[J].汕头大学学报,2000,15(2)：46-49.
[22]杜银忠.3种中药对产酶菌R质粒消除作用的研究[J].青海大学学报,2009,27(1)： 78-79.
[23]陈小英.大黄素对金黄色葡萄球菌抗生素耐药质粒的消除作用[J].南京药学院学报,1985(16)2：48-51.
[24]祁汝峰,黄瑞,祁小飞.中西药消除耐药质粒pRST98的研究[J].中国血液流变学杂志,2004,14(1)：46-47.
[25]雷连成,韩文瑜,段艳.大肠杆菌耐药性抑制作用机制的初步研究[J].中国兽药杂志,2004,38(2)：18-21.
[26]李仝,胡凯文,陈信义,等.浙贝母对呼吸系统耐药金黄色葡萄球菌逆转作用的临床研究.北京中医药大学学报,2001,9,24(5)：51-52.
[1]刘建梅,陈强,李岚,等.痰热清注射液佐治小儿呼吸道感染60例[J].实用儿科临床杂志,2005,20(10)：1040.
[2]陈淑娟.痰热清联合西药治疗老年慢性支气管炎急性发作期的疗效观察[J].辽宁中医药大学学报2009,11(8)：154-155.
[3]吴晓明.痰热清注射液治疗慢性阻塞性肺疾病急性加重期例[J].中国中医急症2010,19(4)：659.
[4]李国勤,边永君.痰热清结合抗生素治疗急性细菌性肺炎50例[J].中国新药杂志,2008,17(6)：509-511.
[5]杨罡.痰热清注射液治疗社区获得性肺炎疗效研究[J].时珍国医国药,2007,18(8)：2017-2018.
[6]曹雪松,林治范,王玉昆.痰热清治疗肺结核124例疗效观察[J].中国当代医药2009,16(10)：146.
[7]郭海彬,柴世磊.痰热清注射液治疗肺脓肿50例[J].2009,29(8)：815-816.
[8]石莹.痰热清注射液治疗病毒性上呼吸道感染高热40例[J].浙江中医杂志,2009,44(8)：621.
[9]甲型H1N1流感诊疗方案[EB/OL].http://www.chinac2dc.Net.cn/n272442/n272530/ n273736/n273781/n4624704/n4624714/3107.html,2009.
[10]李刚.痰热清注射液联合奥司他韦治疗甲型H1N1流感疗效观察[J].中国中医急症,2010,19(10)：1681-1682.
[11]陈强,石正禄.痰热清注射液治疗病毒性肺炎疗效观察[J].中国中医急症,2008,17(12)：689.
[12]谭正炳.痰热清联合头孢噻肟钠治疗肝硬化并自发性腹膜炎临床体会[J].中国中医急症,2008,17(11)：1613.
[13]李小梅,宋盛青.痰热清注射液治疗急性胆囊炎38例[J].中医研究,2007(20)8：39-41.
[14]李克明,鲁厚胜.痰热清注射液治疗急性泌尿系统感染疗效观察[J].中国中医急症,2007,16(5)：542.
[15]刘启如,方平安.痰热清注射液治疗流行性乙型脑炎临床观察[J].中国中医急2008,(17)：1201.
[16]黄章.痰热清联合利巴韦林治疗儿童手足口病的临床分析[J].中外医疗,2009,27：84-85.
[17]杨军,魏敏.痰热清注射液治疗麻疹疗效观察[J].西南国防医药,2008,(18)5：693-
[18]谭正炳.痰热清注射液治疗登革热疗效观察[J].中外医疗,2008 N0.23：75.
[19]杜晓华,张力燕.痰热清注射液对AECOPD患者肺功能和炎症因子的影响[J],中国中医急症,2009,18(12)：1952.
[20]罗光伟,孙洁民,毛先明.痰热清注射液对痰热壅肺型COPD急性加重期C反应蛋白的影响[J].中国中医急症,2009,18(12)：1954-1955.
[21]龚国良,李欣.痰热清治疗慢性阻塞性肺疾病急性加重期的临床疗效及细胞因子水平的研究[J].中国中药杂志,2009,34(1)：104-106.
[22]廖振荣.痰热清注射液对COPD急性发作患者血清IL-17和IL-8表达的影响[J].医学研究杂志,2009,38(7)：103-105.
[23]余应喜,刘景仑.痰热清注射液对ICU呼吸机相关性肺炎患者CRP、IL-6和TNF-a的调节作用[J].中国中医急症2009,18(2)：184-185.
[24]胡庆全,痰热清注射液对老年慢性支气管炎急性发作患者体液免疫及肿瘤坏死因子α浓度的影响[J].中成药,2008,3(10)：1415-1417.
[25]张静,王晓红,杨俊泉,胡万宁,张瑞娟.痰热清注射液对血浆IL-6及ACE影响及防治放射性肺炎疗效观察[J].使用实用预防医学,2009(16)5：1537-1539.
[26]王晓红.痰热清注射液对血浆内皮素-1的影响及防治放射性肺损伤的疗效观察[J].中国煤炭工业学杂志,2008,11(12)：1823-1825.
[27]杨晓刚,郭德和,何进喜.心脏瓣膜置换术患者围手术期细胞因子TNF-a, IL-6的变化及痰热清注射液对其的影响[J].第四军医大学学报,2009,30(21)：2379-2381.
[28]黄登鹏,彭卫平,陈少武,伍华梅.痰热清注射液治疗重症急性胰腺炎抗炎作用观察[J].中国中医急症,2005,14(2)：117.
[29]牛旭艳,王甫,张春晶.痰热清注射液对FMI感染HEK-293T细胞NF-KB转录活性及TNF-a产生影响的研究[J].中华中医药杂志(原中国医药学报)2008增刊：149-152.
[30]郑金粟,顾立刚.痰热清注射液对流感病毒FM1感染小鼠抗病毒作用的研究[J].中华中医药杂志(原中国医药学报),2009,24(7)：851-854.
[31]刘红菊,张玉.痰热清的抗氧化作用及对急性肺损伤的抑制作用研究[J].中国医院药学杂志,2009,29(19)：1607-1610.
[32]孔祥鸣,吴稚冰.痰热清注射液对急性放射性肺炎大鼠血清TGF-β1水平及肺病理学改变的影响[J].实用中西医结合临床2008,8(4)：85-86.
[33]刘德红,邓哲.痰热清注射液对脓毒症大鼠核因子-κB活性及生存率的影响[J].实用医学杂志2008,24(13)：2208-2210.
[34]徐晓月,等.3种痰热清胶囊小鼠体内抗流感病毒作用的比较[J].抗感染药学2005,5(3)：142-144.
[1]Kumarasamy K K, Toleman M A, Walsh T R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK:a molecular, biological, and epidemiologicalstudy[J]. Lancet Infect Dis,2010,10(9):597-602.
[2]Boseley S. Are you ready for a world without antibiotics? [EB/OL]. Guardian, co. uk,2010-8-11, http://www.guardian.co.uk/society/2010/aug/12/the end of antibiotics health infections.
[3]Donald G, Mcneil J. Antibiotic-resistant bacteria moving fromsouth Asia to U.S. [N]. New York Times,2010,8,11.
[4]戴德银,康晓曦,张燕.“超级细菌”现状及防治对策[J].现代临床医学,2010,36(6)：414.
[5]Patermn DL, Bonomo RA. Extended-spectrum beta-lactamases:a clinical update. Clin MicrobiolRev,2005,18 (4):657-686.
[6]Hadziyannis E, Tuohy M, ThomasL, atel. Screening methods for detection of extende-spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella oxytoca clinical isolates [J]. DiagnMicrobiolInfectDisease,2000,36:113-117.
[7]Ho PL, TsangDN, QueTL, atel. Comparison of screening methodsfor detection of extended-spectrum beta-lactamases and their prevalence among Escherichia coli and Klebsiella species in HongKong[J]. APM ITS,2000,108:237-240.
[8]张秀珍,胡云建,艾小曼,许宏涛.Mohnarin 2006-2007年度报告：华北地区细菌耐药监测[J].中国抗生素杂志,2008,33(10)：616-621.
[9]陈茶,黄彬,张文.产ESBLs大肠埃希菌及肺炎克雷伯菌的基因分型研究[J].广东医 学,2006,27(5)：686-687.
[10]胥飚,曹何,余显书.肠杆菌科产超广谱β-内酰胺酶菌株的耐药性及基因型分析[J].重庆医科大学学报,2004,29(6)：781-783.
[11]胡云建,俞云松,张秀珍,等.产超广谱β-内酰胺酶细菌的分子流行病学研究[J].中华医院感染学杂志,2004,14(3)：241-244.
[12]庞众多,任君慧,陈永红.产超广谱p-内酰胺酶大肠埃希菌的检测[J].中国卫生检验杂志,2009,19(3)：619-620.
[13]叶素娟,杨青,俞云松.2005年中国CHINET大肠埃希菌和肺炎克雷伯菌耐药性分析[J].中国感染与化疗杂志,2007,7(4)：283-286.
[14]卓超,苏丹虹,朱德妹.2007年中国CHINET大肠埃希菌和肺炎克雷伯菌耐药性分析[J].中国感染与化疗杂志,2009,9(3)：185-191.
[15]汪复,朱德妹,胡付品,等.2009年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2010,10(5)：325-334.
[16]张珍珍,吴俊伟,杨卫军.大肠埃希氏菌对β-内酰胺类抗生素耐药机制的研究进展[J].中国兽药杂志,2008,42(7)：36-40.
[17]吴佳丽,顾洪琴,俞云松,等.杭州市产超广谱p-内酰胺酶菌株耐药性和基因型分布研究[J].浙江医学,2005,27(6)：401-403.
[18]季淑娟,陈亚岗,俞云松,等.浙江省产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的基因分型[J].中华传染病杂志,2005,23(2)：75-79.
[19]季淑娟,顾怡明,谭文涛,等.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因型研究[J].中华检验医学杂志,2004,27(9)：590-593.
[20]俞云松.超广谱β-内酰胺酶研究概况[J].中国抗生素杂志,28(12)：712.
[21]王华丽.大肠埃希菌耐药机制研究及进展[J].国外医药抗生素分册2005,26(3)：133-136.
[22]BonnetR. Growing Group of Extended-spectrum β-lactamases:the CTX-M Enzymes [J]. AntimicrobialAgentsChemotherapy,2004,48(1):1-14.
[23]陆坚,唐英春,张扣兴,等.CTX-M-14型超广谱β-内酰胺酶基因的定点突变研究[J].中华微生物学和免疫学杂志,2003,23(10)：800-804.
[24]李虹玲,刘文恩.SHV型超广谱β-内酰胺酶的研究进展[J].实用预防医学,2007,14(1)：253-255.
[25]Pena. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect,2006,12 (3):279-284.
[26]吕晓菊.肠杆菌科产超广谱β内酰胺酶细菌耐药性研究进展[J].国外医学抗生素分册,2001,22(2)：66-69.
[27]陈升汶,卢月梅,张阮章,等.大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因分型研究[J].中华检验医学杂志,2006,29(2)：166-167.
[28]段建春,吕晓菊,赵燕,等.产ESBLs肠杆菌科细菌对氨基糖苷类抗生素耐药机制研究[J].中国抗生素杂志,2005,30(9)：555-558.
[29]Delonetcr, Schiller N L. Characterization of an in Vitro selected amoxicillin-resistant strain of Helicobacterpylori[J]. Antimicrob Agents Chemother, 2000,44 (11):3368-3373.
[30]陈亚岗,俞云松,周伟琳,等.浙江省产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌流行情况及耐药性[J],中华传染病学杂志,2000,18：263.
[1]刘文静,张小江,杨文航.2008年北京协和医院细菌耐药性监测结果分析[J].中国感染与化疗杂志,2010,10(4)：290-295.
[2]汪复,朱德妹,胡付品.2009年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志2010,10(5)：325-334.
[3]陈贤华,梁思群.2003-2007年大肠埃希菌耐药性监测分析[J].现代医药卫生,2008,24(15)：2269-2270.
[4]高娅文,杨宇,吴悦陶.抗菌药物使用与产超广谱β-内酰胺酶的关系[J].中华医院感染学杂志,2009,19(20)：2763-2765.
[5]王淑峰,戎建荣.大肠埃希菌β-内酰胺酶基因分型与耐药性研究[J].中华医院感染学杂志,2009,19(17)：2236-2238.
[6]裴保香,郭绍来,王睿,等.大肠埃希菌耐药性与头孢菌素类用量变化的相关性分析[J].中华医院感染学杂志,2004,14(4)：373-376.
[7]Colodner R. Extended-spectrum beta-lactamases:a challenge for clinical microbiologist and infection control specialists[J]. Am J Infect Control, 2005,33 (2):104-107.
[8]MendelsonG, HaitV, Ben-IsraelJ, etal.Prevalence and risk factors of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniaein an Israeli long term care facility[J]. Eur J Clin Microbiol Infect Dis,2005,24(1):17-22.
[9]林庆安,赖国祥,黄梁浒,等.福州地区肺炎克雷伯氏菌和大肠埃希氏菌的药敏监测[J].中国抗生素杂志,2004,29(2)：79-81.
[10]罗燕萍,张秀菊,徐雅萍,等.产超广谱p-内酰胺酶肺炎克雷伯菌和大肠埃希菌的分布及其耐药性研究[J].中华医院感染学杂志,2006,16(1)：101-104.
[11]管希周,罗燕萍,刘又宁,等.高产AmpC酶肺炎克雷伯菌的临床报道[J].中华医院感染学杂志,2004,14(4)：461-464.
[12]王继东,周丽珍,宫玲玲,等.铜绿假单胞菌的多重耐药基因研究[J].中华医院感染学杂志,2006,16(3)：241-244.
[13]陈瑞,唐英春,朱家馨,等.耐亚胺培南铜绿假单胞菌的耐药性及分子流行病学研究[J].中华医院感染学杂志,2006,16(4)：371-373.
[1]贾云鹏,程宁.中药对大肠埃希菌抗生素耐药性逆转作用的实验研究[J].陕西中医,2009,30(3)：366-367.
[2]凌保东,谢勇恩,张翔,等.产ESBLs液化沙雷氏菌临床分离株的表型和基因型分析[J].中国抗生素杂志,2003,28(12)：741-743.
[3]闰淑雅,李家泰.革兰阴性杆菌中β-内酰胺酶催化水解头孢氨噻肟动力学[J].中国药理学报,1988,9：448-452.
[4]高益民,王忠山.对痰热清注射液临床药学初步评价[J].首都医药,2004,4(12)：44- 46.
[5]李显志译.细菌的耐药性.国外医药抗生素分册,1995,16(1)：30.
[6]王静,张淑文.中药逆转细菌耐药的研究进展[J].临床和实验医学志,2007,6(1)：153.
[7]黄通旺,杨撷强,庞珊.抑制β-内酰胺酶的中草药的筛选研究[J].汕头大学学报(自然科学版),2000,15(2)：200.
[8]黄通旺,杨撷强.庞珊.抑制β-内酰胺酶的中草药的筛选研究[J].汕头大学学报(自然科学版),2000,15(2)：200.
[9]杜军,李敏.产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌耐药性及基因型研究[J].中国抗生素杂志,2009,34(8)：512.
[10]郑为平,史伟峰.产超广谱β-内酰胺酶大肠埃希菌相关耐药基因研究[J].中华医院感染学杂志,2009,19(13)：1629-1630.
[11]Livermore DM. Beta-lactamases in laboratory and clinical resistance[J]. Clin Microbiol Rev,1995,8:557-584.
[12]张珍珍,吴俊伟,杨卫军.大肠埃希氏菌对β-内酰胺类抗生素耐药机制的研究进展[J].中国兽药杂志,2008,42(7)：36-40.
[13]BonnetR. Growing Group of Extended-spectrum β-lactamases:the CTX-MEnzymes [J].AntimicrobialAgentsChemotherapy,2004,48(1):1-14.
[14]陆坚,唐英春,张扣兴,等.CTX-M-14型超广谱β-内酰胺酶基因的定点突变研究[J].中华微生物学和免疫学杂志,2003,23(10)：800-804.
[15]陈民钧.细菌耐药性及其临床意义[J].中华外科杂志,1998,36(A00)：6-8.
[16]童明庆,刘根焰.细菌耐药与临床对策[J].临床检验及实验室设备,2005,6(2)：32-33.
[17]Nikaido H Outer membrane barrier as a mechanism of antimicrobial resistance Antimicrob Agents Chemother,1989,33:1831-1836.
[18]雷连成,韩文瑜,段艳.大肠杆菌耐药性抑制作用机制的初步研究[J].中国兽药杂志,2004,38(2)：18-21.
[19]Nishino K, Yamada J,Hirakawa H, et al. Roles of TolC-dependent multidrug transporters of Escherichia coli in resistance to β-lactams[J]. Antimicrob AgentsChemother,2003,47 (9):3030.
[20]李仝,胡凯文,陈信义,等.浙贝母对呼吸系统耐药金黄色葡萄球菌逆转作用的临床研究[J].北京中医药大学学报,2001,9,24(5)：51-52.
[21]王华丽.大肠埃希菌耐药机制研究及进展[J].国外医药抗生素分册2005,26(3)：133-136.
[22]雷连成,韩文瑜.大肠杆菌耐药性中药抑制剂的初步研究[J].吉林农业大学学报2003,25(4)：429-433.
[23]王本祥.现代中药药理学[M].天津：天津科学技术出版社,1997：1-2.